Search
Xanomeline
go.drugbank.com/drugs/DB15357ApprovedInvestigational[A264514] Xanomeline is a muscarinic agonist that was approved for the treatment of schizophrenia by the FDA in September 2024, becoming the first approved treatment for schizophrenia to target muscarinic … receptors as opposed to dopamine receptors.
Copanlisib
go.drugbank.com/drugs/DB12483ApprovedInvestigational[A261730] Copanlisib was granted accelerated approval by the FDA in September 2017 for the treatment of follicular lymphoma.[A261725]
Cerivastatin
go.drugbank.com/drugs/DB00439ApprovedWithdrawnFood and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from
Diethylcarbamazine
go.drugbank.com/drugs/DB00711ApprovedInvestigationalVet approvedWithdrawnAn anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.
Daratumumab
go.drugbank.com/drugs/DB09331ApprovedInvestigationalDaratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. … approval was based on results from the Phase 3 PERSEUS study, which demonstrated significant improvement in progression-free survival and higher rates of minimal residual disease (MRD) negativity compared to
Belatacept
go.drugbank.com/drugs/DB06681ApprovedInvestigationalBelatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). … Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human
Categories: Selective T Cell Costimulation Blocker, T Lymphocyte Costimulation Activity BlockadeFlavin mononucleotide
go.drugbank.com/drugs/DB03247ApprovedInvestigational[L54226] In addition to its systemic use as a means of riboflavin supplementation, a topical ophthalmic preparation of FMN was approved by the FDA in October 2025 for use as a photoenhancer in epithelium-on … [A274616,L54226] FMN is composed of an isoalloxazine ring - which serves as the active redox center - attached to a ribityl phosphate chain.
Ledipasvir
go.drugbank.com/drugs/DB09027ApprovedLedipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … This is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid development of resistance has proven to be an important cause of therapeutic failure
Enzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigationalCompared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.[A252667] … [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.
Chlorothiazide
go.drugbank.com/drugs/DB00880ApprovedInvestigationalVet approvedA thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)